Objective To observe the efficacy of Benazepril combined with Telmisartan in the treatment of patients with early diabetic nephropathy,and to provide strong theoretical support for the clinical treatment of diabetic nephropathy.Methods 62 patients diagnosed early diabetic nephropathy in Fushun Central Hospital from January 2010 to January 2012 were selected and divided into a study group of 32 patients confirmed application Benazepril Telmisartan therapy treatment,the control group of 30 patients confirmed application Benazepril treatment,total treatment for 12 weeks.The clinical efficacy rate was observed after treatment for 12 weeks.And the urinary albumin excretion rate (UAER) and fasting plasma glucose (FPG) and 2-hour postprandial blood glucose (2 h PBG),blood urea nitrogen (BUN),serum creatinine (Scr) changes were observed after treatment for 3,6 and 12 months.Results After 12 weeks of treatment,the markedly effective rate of study group was 56.25％,the total effective rate of study group was 93.75％,markedly effective rate of the control group was 40.00％,the total effective rate of the control group 70.00％,the markedly effective rate had no significant difference between two groups (P ＞ 0.05).The difference was significant of total effective rate of the two groups (P ＜ 0.05).After treatment for 3,6 and 12 months,FBG,2 h PBG of the study group and the control group decreased than before treatment,but the differences were not significant (P ＞ 0.05).And after treatment for 3,6,and 12 months,differences of FBG,2 h PBG of the two groups at different time points were not statistically significant (P ＞ 0.05).After treatment for 3,6 and 12 months,UAER of the study group and the control group compared with pre-treatment significantly reduced,the difference was significant (P ＜ 0.05).The UAER level of the study group after treatment for 3,6 and 12 months,compared with the control group,the UAER of the study group significantly decreased,the difference was significant (P ＜ 0.05).The Scr of the study group significantly reduced after treatment for 3,6 and 12 months and reduced than before treatment,the difference was extremely significant (P ＜ 0.05).Scr level of the control group after treatment 3,6 and 12 months reduced than before treatment,the difference was significant (P ＜ 0.05).Scr of the study group after treatment 3,6 and 12 months compared with the control group decreased significantly,and the difference was significant (P ＜ 0.05).Conclusion Benazepril and Telmisartan in the treatment of early diabetic nephropathy has a synergistic effect to reduce urinary protein excretion,which plays a role to protect kidney function.%目的 观察贝那普利联合替米沙坦治疗早期糖尿病肾病患者的疗效,旨在为临床治疗糖尿病肾病提供有力的理论支持.方法 选择辽宁省抚顺市中心医院2010年1月～2012年1月住院治疗确诊的早期糖尿病肾病患者62例,将确诊的糖尿病肾病患者随机分为两组,研究组32例,应用贝那普利联合替米沙坦治疗,对照组30例,应用贝那普利治疗.疗程12周.观察两组患者治疗12周后的疗效以及两组患者治疗前及治疗后3、6、12个月尿微量白蛋白排泄率(UAER)、空腹血糖(FPG)、餐后2h血糖(2 h PBG)、尿素氮(BUN)、血肌酐(Scr)的变化情况.结果 治疗12周后,研究组的显效率达56.25％,总有效率达93.75％,对照组的显效率达40.00％,总有效率达70.00％,两组显效率比较差异无统计学意义(P＞0.05),两组总有效率比较差异有统计学意义(P＜ 0.05).研究组和对照组患者治疗后3、6、12个月的FBG、2 h PBG均较治疗前降低,但差异无统计学意义(P＞0.05).且两组患者治疗后3、6、12个月不同时间点的FBG、2 h PBG,差异无统计学意义(P＞0.05).研究组和对照组的UAER治疗后3、6、12个月分别较治疗前明显降低,差异有统计学意义(P＜0.05).且研究组治疗后3、6、12个月UAER水平分别较对照组降低更明显,差异有统计学意义(P＜0.05).研究组的Scr水平治疗后3、6、12个月分别较治疗前显著降低,差异有统计学意义(P＜ 0.05).对照组的Scr水平治疗后3、6、12个月分别较治疗前降低,差异有统计学意义(P＜0.05).且研究组治疗后3、6、12个月Scr水平分别较对照组降低更明显,差异有统计学意义(P＜0.05).结论 贝那普利联合替米沙坦治疗早期糖尿病肾病疗效好,二者具有协同作用,能减少尿蛋白的排泄,从而起到保护肾脏功能的作用.
展开▼
